Peroxisome Proliferator Activated Receptor Delta NUCI or Nuclear Hormone Receptor 1 or Nuclear Receptor Subfamily 1 Group C Member 2 or Peroxisome Proliferator Activated Receptor Beta or NR1C2 or PPARD Pipeline Review, H2 2018
Summary
Peroxisome Proliferator Activated Receptor Delta NUCI or Nuclear Hormone Receptor 1 or Nuclear Receptor Subfamily 1 Group C Member 2 or Peroxisome Proliferator Activated Receptor Beta or NR1C2 or PPARD Peroxisome proliferatoractivated receptor delta is a nuclear receptor that in humans is encoded by the PPARD gene. PPARdelta is a nuclear hormone receptor that governs a variety of biological processes and involved in the development of several chronic diseases, including diabetes, obesity, atherosclerosis, and cancer. The expression of this gene is found to be elevated in colorectal cancer cells. The elevated expression can be repressed by adenomatosis polyposis coli APC, a tumor suppressor protein involved in the APC/betacatenin signaling pathway.
Peroxisome Proliferator Activated Receptor Delta NUCI or Nuclear Hormone Receptor 1 or Nuclear Receptor Subfamily 1 Group C Member 2 or Peroxisome Proliferator Activated Receptor Beta or NR1C2 or PPARD pipeline Target constitutes close to 14 molecules. Out of which approximately 12 molecules are developed by companies and remaining by the universities/institutes.
The molecules developed by companies in Phase III, Phase II, Phase I and Preclinical stages are 3, 4, 3 and 2 respectively. Similarly, the universities portfolio in Discovery stages comprises 2 molecules, respectively. Report covers products from therapy areas Metabolic Disorders, Gastrointestinal, Central Nervous System, Genito Urinary System And Sex Hormones, Genetic Disorders, Immunology, Musculoskeletal Disorders, Oncology, Ophthalmology, Respiratory and Undisclosed which include indications NonAlcoholic Steatohepatitis NASH, Acute Renal Failure ARF Acute Kidney Injury, Duchenne Muscular Dystrophy, Dyslipidemia, Liver Diseases, Non Alcoholic Fatty Liver Disease NAFLD, Primary Biliary Cirrhosis, Type 2 Diabetes, Alzheimer's Disease, Bone Disorders, Bone Fracture, Colitis, Familial Chylomicronemia Type I Hyperlipoproteinemia, Homozygous Familial Hypercholesterolemia HoFH, Hypertriglyceridemia, Idiopathic Pulmonary Fibrosis, Inflammation, Keratoconjunctivitis sicca Dry Eye, Kidney Disease, Leber's Hereditary Optic Neuropathy LHON Leber optic atrophy, Liver Fibrosis, MELAS Syndrome Mitochondrial Encephalomyopathy, Lactic Acidosis and StrokeLike Episodes, Metabolic Syndrome, Mitochondrial Diseases, Neurodegenerative Diseases, Osteoarthritis, Osteoporosis, Parkinson's Disease, Systemic Sclerosis Scleroderma and Unspecified.
The latest report Peroxisome Proliferator Activated Receptor Delta Pipeline Review, H2 2018, outlays comprehensive information on the Peroxisome Proliferator Activated Receptor Delta NUCI or Nuclear Hormone Receptor 1 or Nuclear Receptor Subfamily 1 Group C Member 2 or Peroxisome Proliferator Activated Receptor Beta or NR1C2 or PPARD targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action MoA, route of administration RoA and molecule type. It also reviews key players involved in Peroxisome Proliferator Activated Receptor Delta NUCI or Nuclear Hormone Receptor 1 or Nuclear Receptor Subfamily 1 Group C Member 2 or Peroxisome Proliferator Activated Receptor Beta or NR1C2 or PPARD targeted therapeutics development with respective active and dormant or discontinued projects.
The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industryspecific third party sources.
Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
Scope
The report provides a snapshot of the global therapeutic landscape for Peroxisome Proliferator Activated Receptor Delta NUCI or Nuclear Hormone Receptor 1 or Nuclear Receptor Subfamily 1 Group C Member 2 or Peroxisome Proliferator Activated Receptor Beta or NR1C2 or PPARD
The report reviews Peroxisome Proliferator Activated Receptor Delta NUCI or Nuclear Hormone Receptor 1 or Nuclear Receptor Subfamily 1 Group C Member 2 or Peroxisome Proliferator Activated Receptor Beta or NR1C2 or PPARD targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industryspecific sources
The report covers pipeline products based on various stages of development ranging from preregistration till discovery and undisclosed stages
The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, RD brief, licensing and collaboration details other developmental activities
The report reviews key players involved in Peroxisome Proliferator Activated Receptor Delta NUCI or Nuclear Hormone Receptor 1 or Nuclear Receptor Subfamily 1 Group C Member 2 or Peroxisome Proliferator Activated Receptor Beta or NR1C2 or PPARD targeted therapeutics and enlists all their major and minor projects
The report assesses Peroxisome Proliferator Activated Receptor Delta NUCI or Nuclear Hormone Receptor 1 or Nuclear Receptor Subfamily 1 Group C Member 2 or Peroxisome Proliferator Activated Receptor Beta or NR1C2 or PPARD targeted therapeutics based on mechanism of action MoA, route of administration RoA and molecule type
The report summarizes all the dormant and discontinued pipeline projects
The report reviews latest news and deals related to Peroxisome Proliferator Activated Receptor Delta NUCI or Nuclear Hormone Receptor 1 or Nuclear Receptor Subfamily 1 Group C Member 2 or Peroxisome Proliferator Activated Receptor Beta or NR1C2 or PPARD targeted therapeutics
Reasons to buy
Gain strategically significant competitor information, analysis, and insights to formulate effective RD strategies
Identify emerging players with potentially strong product portfolio and create effective counterstrategies to gain competitive advantage
Identify and understand the targeted therapy areas and indications for Peroxisome Proliferator Activated Receptor Delta NUCI or Nuclear Hormone Receptor 1 or Nuclear Receptor Subfamily 1 Group C Member 2 or Peroxisome Proliferator Activated Receptor Beta or NR1C2 or PPARD
Identify the use of drugs for target identification and drug repurposing
Identify potential new clients or partners in the target demographic
Develop strategic initiatives by understanding the focus areas of leading companies
Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
Devise corrective measures for pipeline projects by understanding Peroxisome Proliferator Activated Receptor Delta NUCI or Nuclear Hormone Receptor 1 or Nuclear Receptor Subfamily 1 Group C Member 2 or Peroxisome Proliferator Activated Receptor Beta or NR1C2 or PPARD development landscape
Develop and design inlicensing and outlicensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope